"DaVita Kidney Care is a division of DaVita Inc., a Fortune 500 company, providing a variety of health care services to patients suffering with kidney disease throughout the United States and abroad. Our dialysis centers provide hemodialysis and peritoneal dialysis to help treat patients with chronic kidney failure and end stage renal disease. We strive to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, home dialysis, personalized care teams and convenient health-management services."

During the past decade, Med Center Dialysis conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 4 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Med Center Dialysis" #1 sponsor was "Pfizer" with 2 trials, followed by "Reata Pharmaceuticals, Inc." with 2 trials sponsored, "Ardelyx" with 1 trials sponsored, "Keryx Biopharmaceuticals" with 1 trials sponsored and "Shire" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Med Center Dialysis" #1 collaborator was "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Med Center Dialysis" are "Hyperphosphatemia" (3 trials), "Autosomal Dominant Polycystic Kidney" (2 trials), "ADPKD" (1 trials), "Alport Syndrome" (1 trials) and "Chronic Kidney Disease" (1 trials). Many other conditions were trialed in "Med Center Dialysis" in a lesser frequency.

Most popular intervention types in "Med Center Dialysis" are "Drug" (4 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Epoetin Hospira" (2 trials), "Bardoxolone methyl" (1 trials), "Bardoxolone methyl oral capsule" (1 trials), "Epogen (Amgen)" (1 trials) and "Phosphate Binder Agents" (1 trials). Other intervention names were less common.

The vast majority of trials in "Med Center Dialysis" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Med Center Dialysis". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Med Center Dialysis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Med Center Dialysis, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".